Study 1244
We are looking for healthy participants for a clinical trial involving an investigational drug for the treatment of inflammatory diseases.
The purpose of the study is to investigate the drug’s safety and tolerability, as well as how it is absorbed, distributed, and excreted in the body.
Target group: healthy individuals, ages 18–60
Criteria for participation:
- Be healthy
- BMI between 18 and 34kg/m²
- Do not have atopic conditions (e.g., atopic eczema)
- Do not use nicotine products regularly
- Do not take any medications or dietary supplements
- Must not have participated in another drug study in the last three months
- Have not donated blood in the past three months
- Be willing to use a double barrier method for heterosexual intercourse, i.e., condom/be sterile (men) AND have approved contraception/be sterile/postmenopausal (women)
The study consists of three visits to our clinic in Uppsala: a health screening, a dosing visit, and a follow-up visit. During the dosing visit, you will stay overnight at the clinic for three days and receive a dose of the study drug or a placebo.
Compensation: 10,900 SEK for your participation.
Schedule
| GROUP | Health check-up (visit 1) | Inpatient stay at the clinic (visit 2) | Follow-up Visit (Visit 3) |
| 1:1 | Dec. 1, Dec. 3 | Dec. 16–19 | Dec. 28 |
| 1:2 | Dec. 1, Dec. 3 | Dec. 17–20 | Dec. 28 |
| 1:3 | Dec. 1, Dec. 3 | Dec. 20–23 | Dec. 29 |
More information and registration
Would you like to participate in the study?Please submit an expression of interest using the form below.
Do you have any questions or want to know more?Call 018-30 33 99 or emailinfo@ctc-ab.se.
The study has been approved by the Swedish Ethical Review Authority and the Swedish Medical Products Agency. Your participation is voluntary, and you may withdraw at any time. The information you provide will be processed in accordance with the General Data Protection Regulation (GDPR).




